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LAA endocardium 8 . Patients in whom a thrombus was described were temporarily withdrawn from were classified according to the current guidelines on Chamber Quantification 9 .
1
The study was performed in accordance to the latest Declaration of Helsinki and patients at each 2 center provided written informed consent to undergo TEE. patients undergo TEE prior to AF ablation, without major significant regional differences 13 . 15 Our study included a selected population of patients without major structural 16 cardiomyopathies undergoing AF ablation and is, to the best of our knowledge, the largest available 17 series assessing this issue. Despite the strict selection criteria, the population included in our study is 18 well representative of a relevant share of subjects undergoing AF ablation in European centers in the 19 time span considered for our analysis 13 . A very low prevalence of LA/LAA thrombi is reported, 20 however the prospective study by Puwanant et al. reported a similar prevalence of LAA thrombi 21 (0.6%) 6 ; in the European Atrial Fibrillation Ablation Pilot Study 7 patients out of 1410 did not 22 undergo AF ablation due to a LAA thrombus. A slightly higher prevalence was reported instead in 23 other experiences (ranging between 1.6%-3.6%), that, however, included patients at higher risk of 24 thrombotic events who were excluded in our multicenter study (e.g. history of congestive heart failure, structural heart disease, cardiomyopathies and valvular heart disease) 14 In general, the present is a highly selected population with a low probability of LAA thrombi. 3 Generalization of the present findings is therefore bound to subjects with similar characteristics. In the risk-benefit ratio of its use in the AF ablation setting should be carefully re-assessed. TEE 12 presents a low, but still not negligible, risk of complications (0.8-2.8%) 5 , and, in addition, may 13 determine an unjustified increase in the health-care related costs other than being often poorly 14 tolerated by the patients 23 .
In conclusion, in our opinion, a careful risk/benefit ratio evaluation and 15 prospective studies are needed to corroborate the comparative safety of an extensive vs. selective use 16 of TEE prior to AF ablation. 17 
18
Study limitations 19 The following limitations must be taken into account. First, this report is retrospective: 20 study cohort may therefore be biased by patient selection by physician in charge. Second, 21 multivariate analysis is based on a low number of events and is consequently limited in 22 statistical power. The results of our study have consequently to be considered primarily 23 as hypothesis generating. Third, as the aim of our study was to identify easily available 24 features relating to the presence of LA/LAA thrombi, advanced and TEE parameters were 25 intentionally not included in the analysis. More specifically, thorough diastolic (i. 
Conclusions

12
The present study shows that careful patient selection and a simple clinical assessment including 13 CHA 2 DS 2 -VASc score, heart rhythm on admission, and ablation history may identify a relevant 14 subset of patients with a very low probability of LA/LAA thrombi, who could be potentially safely 15 spared from TEE before AF transcatheter ablation. 16 17 Acknowledgments: to all the cardiologists, cardiology fellows and paramedics assisting or 18 performing the procedures and collecting the data that contributed to the realization of this study. 
